State Board of Administration of Florida Retirement System lowered its position in Haemonetics Corp. (NYSE:HAE) by 1.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,993 shares of the company’s stock after selling 483 shares during the period. State Board of Administration of Florida Retirement System owned about 0.08% of Haemonetics Corp. worth $1,246,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in HAE. Goldman Sachs Group Inc. increased its stake in shares of Haemonetics Corp. by 1,068.1% in the first quarter. Goldman Sachs Group Inc. now owns 231,128 shares of the company’s stock worth $8,085,000 after buying an additional 211,341 shares during the period. State Street Corp increased its stake in shares of Haemonetics Corp. by 1.1% in the first quarter. State Street Corp now owns 1,030,394 shares of the company’s stock worth $36,042,000 after buying an additional 11,371 shares during the period. Menta Capital LLC acquired a new stake in shares of Haemonetics Corp. during the first quarter worth about $479,000. JPMorgan Chase & Co. increased its stake in shares of Haemonetics Corp. by 13,722.5% in the first quarter. JPMorgan Chase & Co. now owns 34,418 shares of the company’s stock worth $1,204,000 after buying an additional 34,169 shares during the period. Finally, BlackRock Institutional Trust Company N.A. increased its stake in shares of Haemonetics Corp. by 1.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,277,588 shares of the company’s stock worth $44,690,000 after buying an additional 12,466 shares during the period. 98.78% of the stock is owned by institutional investors.

Shares of Haemonetics Corp. (NYSE:HAE) traded down 0.94% during trading on Tuesday, reaching $36.88. The company had a trading volume of 271,008 shares. The stock has a 50 day moving average of $36.22 and a 200 day moving average of $32.19. The stock’s market capitalization is $1.89 billion. Haemonetics Corp. has a 52-week low of $25.98 and a 52-week high of $38.06.

Haemonetics Corp. (NYSE:HAE) last posted its quarterly earnings data on Monday, August 1st. The company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. The firm earned $210 million during the quarter, compared to analysts’ expectations of $205.41 million. Haemonetics Corp. had a negative net margin of 7.25% and a positive return on equity of 10.75%. The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.35 earnings per share. Equities research analysts forecast that Haemonetics Corp. will post $1.44 EPS for the current year.

HAE has been the topic of a number of research analyst reports. CJS Securities cut Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Sidoti cut Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 target price on the stock. in a research report on Monday, August 15th. Zacks Investment Research cut Haemonetics Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. Barrington Research cut Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 3rd. Finally, Benchmark Co. lifted their target price on Haemonetics Corp. from $28.00 to $32.00 and gave the stock a “hold” rating in a research report on Tuesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. Haemonetics Corp. presently has a consensus rating of “Hold” and an average target price of $34.40.

In other Haemonetics Corp. news, Director Ronald Merriman sold 4,337 shares of the company’s stock in a transaction dated Wednesday, August 17th. The shares were sold at an average price of $35.14, for a total value of $152,402.18. Following the completion of the transaction, the director now directly owns 22,088 shares of the company’s stock, valued at approximately $776,172.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Christopher Simon acquired 60,000 shares of the firm’s stock in a transaction on Thursday, August 4th. The stock was purchased at an average cost of $35.00 per share, with a total value of $2,100,000.00. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by company insiders.

About Haemonetics Corp.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corp. (NYSE:HAE).

Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.